Lack of antagonism between nicorandil and sulfonylurea in stable angina pectoris.
The aim of this study was to clarify whether or not nicorandil (a potassium channel opener) caused adverse reactions in patients with angina pectoris who also had diabetes mellitus treated with sulfonylurea (a potassium channel inhibitor). Nineteen diabetic patients with angina pectoris were enrolled, eight were treated with glibenclamide (group A) and 11 were not (group B). Treadmill exercise testing and frequency of anginal attacks were used to evaluate the severity of angina pectoris. Blood sugar and hemoglobin A1c were measured for evaluation of diabetes mellitus control. Exercise tolerance, frequency of anginal attacks and diabetes mellitus control were not perturbed by treatment in either group. In conclusion, there were no antagonistic reactions from the combination of nicorandil with sulfonylurea in angina pectoris complicated by diabetes mellitus.
Hata
N
N
Department of Internal Medicine, Nippon Medical School, Inbagun, Chiba, Japan. hata-n@nms.ac.jp
Takano
M
M
Kunimi
T
T
Kishida
H
H
Takano
T
T
D000368:Aged; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy*; D001786:Blood Glucose / Q000378:metabolism; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020108:Nicorandil / Q000009:adverse effects* / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000009:adverse effects*; D014665:Vasodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D020108:Nicorandil; D013453:Sulfonylurea Compounds; D014665:Vasodilator Agents